177 related articles for article (PubMed ID: 34616589)
21. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.
Luevano M; Domogala A; Blundell M; Jackson N; Pedroza-Pacheco I; Derniame S; Escobedo-Cousin M; Querol S; Thrasher A; Madrigal A; Saudemont A
PLoS One; 2014; 9(1):e87086. PubMed ID: 24489840
[TBL] [Abstract][Full Text] [Related]
22. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.
Ito M; Hiramatsu H; Kobayashi K; Suzue K; Kawahata M; Hioki K; Ueyama Y; Koyanagi Y; Sugamura K; Tsuji K; Heike T; Nakahata T
Blood; 2002 Nov; 100(9):3175-82. PubMed ID: 12384415
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine in patients with ovarian cancer.
Poveda A
Cancer Treat Rev; 2005; 31 Suppl 4():S29-37. PubMed ID: 16360545
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
26. PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling.
Raja R; Wu C; Bassoy EY; Rubino TE; Utagawa EC; Magtibay PM; Butler KA; Curtis M
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564125
[TBL] [Abstract][Full Text] [Related]
27. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
28. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
[TBL] [Abstract][Full Text] [Related]
29. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
Mimura K; Kamiya T; Shiraishi K; Kua LF; Shabbir A; So J; Yong WP; Suzuki Y; Yoshimoto Y; Nakano T; Fujii H; Campana D; Kono K
Int J Cancer; 2014 Sep; 135(6):1390-8. PubMed ID: 24615495
[TBL] [Abstract][Full Text] [Related]
31. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
32. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
34. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
[TBL] [Abstract][Full Text] [Related]
35. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
37. Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer.
Zhang X; Wang D; Li Z; Jiao D; Jin L; Cong J; Zheng X; Xu L
Front Immunol; 2020; 11():331. PubMed ID: 32161598
[TBL] [Abstract][Full Text] [Related]
38. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
39. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
40. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
